PROM1 and lung cancer: Importantly, our in vivo animal study and clinical data provide the evidence that the amount of Oct-4 in LC-CD133+ (Fig. 7C) and in patients with high-grade lung cancer (Fig. S1) is positively correlated with the degree of resistance to chemoradiation therapy.